Transaction · 0001635088-26-000108

Venker Eric

Venker Eric, PRES, IC, reported a transaction classified as exercise at Roivant Sciences Ltd. involving 200000.000000 shares for an estimated $770000.00. Reported holdings after the transaction were 1799154.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MPRES, IC
ROIVRoivant Sciences Ltd.
Filing timeOct 02
Trade dateSep 30, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableCalculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$35.72
Pre-filing
1mo ago -3.0%1w ago +3.1%1d ago +2.2%
Returns since
7d30d90d180d1y

ROIV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ROIV since 2026-10-02Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001635088-26-000108
Common Shares
Transaction date
Sep 30, 2026
Filed Oct 02, 2026, 09:37 PM · 2d delay
Shares
200k sh
$3.85 per share
Estimated value
$770k
Computed from shares × price
Holdings after
1.79M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & Immunovant CEO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provi…

  2. F2

    Reflects an award of stock options to purchase Common Shares that is fully vested.

Original filing · 0001635088-26-000108
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ROIV